Sandra Ann Springer MD

Associate Professor of Medicine (AIDS) and Associate Clinical Professor of Nursing; Director, Infectious Disease Outpatient Clinic, Veterans Administration Healthcare Services, Newington

Biographical Info

Sandra Springer, MD is an Associate Professor of Medicine in the Department of Internal Medicine, section of Infectious Diseases at the Yale School of Medicine. She is Board-Certified in Internal Medicine, Infectious Diseases and Addiction Medicine. Dr. Springer has significant research experience with adherence interventions for HIV-infected drug and alcohol dependent persons. She was a recipient of a NIDA-funded K23 mentored career development award, during which she evaluated the use of medication assisted treatment (MAT) to prevent relapse to opioid use as a conduit to care among HIV-infected opioid dependent released prisoners. She developed the first protocol to use buprenorphine as relapse prevention for opioid dependent HIV+ prisoners on day of release and has published these findings that serve as proof of concept that MAT can be effective in maintaining HIV+ released prisoners HIV clinical outcomes. She also has expertise in supervising RCTs by serving as medical director and co-investigator for multiple RCTs including DAART adherence interventions for IDUs and HIV+ released prisoners. She also has considerable clinical and research experience with the use of extended-release naltrexone and has been awarded an R01 from NIAAA as Principal Investigator to evaluate its use to prevent relapse to alcohol use among HIV infected alcohol dependent prisoners transitioning to the community and from NIDA as PI as part of the Seek Test Treat and Retain initiative to evaluate its use to prevent relapse to opioid use among opioid dependent released criminal justice populations as a means to maintain HIV treatment outcomes. She is also a co-investigator on an R01 from NIDA with Dr. Altice evaluating the use of buprenorphine as linkage to HIV testing and conduit to care for opioid dependent persons in Washington D.C and a co-investigator for a NIDA R01 with Dr. Altice (PI) that is implementing extended-release naltrexone for opioid dependent persons in Ukraine. She has a K02 independent scientist award from NIDA as well. Dr. Springer has expertise in the development and implementation of medication-assisted-therapy interventions involving HIV+, drug and alcohol dependent persons involved in the criminal justice setting.

International Activity

  • HIV/AIDS and Addiction
    Kiev, Ukraine(2012 - 2017)
    Technical Assistance and Research, implementation protocol for extended-release naltrexone in Ukraine

Education & Training

Harvard University (1990)
University of Massachusetts (1998)
Yale School of Medicine, Internal Medicine (1998 - 2001)
Yale School of Medicine, Infectious Diseases (2001 - 2004)
Board Certification
Infectious Disease, Board Certified  (2005)
Board Certification
Internal Medicine, Board Certified  (2001)

Honors & Recognition

  • Academic Excellence Award for Women in Field of Medicine
    University of Massachusetts Medical School (1998)
  • Award for Outstanding Provider in the Community
    VNA- South Central Partnership (2007)
  • Invited Chair and Discussion of "Integrative Research on Injectable Extended-Release Naltrexone"
    Research Society on Alcoholism (2012)
  • Independent Scientist K-02 Award
    National Institute of Drug Abuse (2011)
  • Invited Reviewer of R01 Grants
    National Institute of Drug Abuse (NIDA) (2011)
  • Recipient of the 2006 B. Jaye Anno Award of Excellence in Communication
  • Mentored Career Development K-23 Award
    National Institute of Drug Abuse (2005)
  • Bristol-Myers Squibb HIV Virology Fellowship Award
    Bristo-Myers Squibb (2002)

Edit Profile